Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis

@article{Ntaios2017RealWorldSC,
  title={Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis},
  author={G. Ntaios and V. Papavasileiou and K. Makaritsis and K. Vemmos and P. Michel and G. Lip},
  journal={Stroke},
  year={2017},
  volume={48},
  pages={2494–2503}
}
Background and Purpose— Evidence from the real-world setting complements evidence coming from randomized controlled trials. We aimed to summarize all available evidence from high-quality real-world observational studies about efficacy and safety of nonvitamin-K oral anticoagulants compared with vitamin-K antagonists in patients with atrial fibrillation. Methods— We searched PubMed and Web of Science until January 7, 2017 for observational nationwide or health insurance databases reporting… Expand
Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials
Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation.
Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
  • M. Hammwoehner, A. Goette
  • Medicine
  • European heart journal supplements : journal of the European Society of Cardiology
  • 2020
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Apixaban versus warfarin in patients with atrial fibrillation.
...
1
2
3
4
5
...